Our top pick for
Building a portfolio
Kintara Therapeutics, Inc is a biotechnology business based in the US. Kintara Therapeutics shares (KTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Kintara Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of USD$48.1 million.
|52-week range||USD$0.5011 - USD$3.35|
|50-day moving average||USD$1.9234|
|200-day moving average||USD$1.6817|
|Wall St. target price||USD$5.81|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-60.25%|
|Return on equity TTM||-266.29%|
|Market capitalisation||USD$48.1 million|
TTM: trailing 12 months
There are currently 613,290 Kintara Therapeutics shares held short by investors – that's known as Kintara Therapeutics's "short interest". This figure is 32.9% down from 914,634 last month.
There are a few different ways that this level of interest in shorting Kintara Therapeutics shares can be evaluated.
Kintara Therapeutics's "short interest ratio" (SIR) is the quantity of Kintara Therapeutics shares currently shorted divided by the average quantity of Kintara Therapeutics shares traded daily (recently around 354502.89017341). Kintara Therapeutics's SIR currently stands at 1.73. In other words for every 100,000 Kintara Therapeutics shares traded daily on the market, roughly 1730 shares are currently held short.
However Kintara Therapeutics's short interest can also be evaluated against the total number of Kintara Therapeutics shares, or, against the total number of tradable Kintara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kintara Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Kintara Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0203% of the tradable shares (for every 100,000 tradable Kintara Therapeutics shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kintara Therapeutics.
Find out more about how you can short Kintara Therapeutics stock.
We're not expecting Kintara Therapeutics to pay a dividend over the next 12 months.
Kintara Therapeutics's shares were split on a 1:10 basis on 7 May 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kintara Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kintara Therapeutics shares which in turn could have impacted Kintara Therapeutics's share price.
Over the last 12 months, Kintara Therapeutics's shares have ranged in value from as little as $0.5011 up to $3.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kintara Therapeutics's is 1.5383. This would suggest that Kintara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.